| Typ : |
Labor |
|
| Forschungsgruppen : |
|
| Autoren : |
|
| Titel : |
Nivolumab (Opdivo®) - Summary of Product Characteristics |
| Veröffentlichung : |
Bristol Myers Squibb Pharmaceuticals 2022 |
|
| Niveau von Beweisen : |
|
| Physikalische Stabilität : |
|
| Chemische Stabilität : |
|
| Andere Verfahren : |
|
| Kommentare : |
|
Molekülverzeichnis
 Nivolumab
|
 |
 |
 |
 |
1 >> 10 mg/ml |
2-8°C |
 |
| 30 |
 |
|
|
|
|
|
1 >> 10 mg/ml |
25°C |
 |
| 24 |
 |
|
|
|
|
 |
1 >> 10 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
1 >> 10 mg/ml |
25°C |
|
| 8 |
|
|
|
|
|
 |
10 mg/ml |
25°C |
|
| 48 |
|
|
|
|
 |
|
1 >> 10 mg/ml |
2-8°C |
|
| 30 |
|
|
|
|
|
|
1 >> 10 mg/ml |
25°C |
|
| 24 |
|
|
|
|
|
|
1 >> 10 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
1 >> 10 mg/ml |
25°C |
|
| 8 |
|
|
|
|
 |
|
1 >> 10 mg/ml |
2-8°C |
|
| 30 |
|
|
|
|
|
|
1 >> 10 mg/ml |
25°C |
|
| 24 |
|
|
|
|
|
|
1 >> 10 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
1 >> 10 mg/ml |
25°C |
|
| 8 |
|
|
|
|
|
